Latest Content

Roughly one-fifth of supplemental indications were approved many years after a drug’s initial launch, many of which target populations with high unmet medical needs.

emtelligent turns unstructured data into coded clinical insights, powering Optum and oncology workflows to improve trial screening, EHR-to-EDC transfer, and decisions.

ViroMissile shares phase 1 IDOV-Safe oncolytic virus results, showing IV activity in pMMR/MSS metastatic colorectal cancer and fueling US phase 2 plans.

At ESMO GI, Merck’s next-generation KRAS-inhibitor calderasib plus EGFR-targeting cetuximab and chemotherapy produce remarkable progression-free survival results for patients with previously untreated colorectal cancer.

Racial gaps in cancer pain care; CGT program reimbursement hurdles; FIB4 liver screening underused; OCM legacy debated; MM bispecifics face access gaps.

From sequencing decisions to economics of care, Adam Kittai, MD, offers a wide-ranging look at top unresolved questions in CLL treatment today.

Real-world data show patients with MASH reach cirrhosis in just 16 months, fueling calls for wider use of fibrosis biomarkers like FIB-4.

Minhee Kang, PharmD, explains how oncology pharmacists translate clinical research into safe, coordinated cancer care.

SYNC-T from Syncromune delivers a 4-part localized immunotherapy regimen for metastatic prostate cancer, showing high response rates with low toxicity.